Report Highlights

The global immunotherapy drugs market is expected to grow from $260.7 billion in 2025 and is projected to reach $467.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% during the forecast period of 2025 to 2030.

Report Includes

• 88 data tables and 57 additional tables
• An overview of the global market for immunotherapy drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022–2024, estimated figures for 2025, and forecasts for 2030, including projections of CAGRs through 2030
• Evaluation of the current market size and revenue growth prospects specific to the immunotherapy drugs, accompanied by a market share analysis by therapy type, application and region
• Description of immunotherapy and combination immunotherapy, and discussion of how it targets cell-mediated adaptive immunity
• Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and new targeted approaches for immunotherapy
• Analysis of the current and future demands in the global immunotherapy drugs, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges and opportunities affecting the market’s growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key companies in the immunotherapy drugs, along with their research priorities, product portfolios, global rankings and the competitive landscape
• Profiles of major companies in industry, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, and Sanofi

Report Scope

The current report provides detailed information on immunotherapy drugs. It analyzes the market trends with data from 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030, including regional markets for immunotherapy drugs. This report highlights the current and future market potential and provides a detailed discussion on the competitive environment. The report will also cover regulatory scenarios, drivers, restraints and opportunities. Additionally, it covers market share data for key companies.

The market in this report is segmented by immunotherapy type into checkpoint inhibitors, monoclonal antibodies (mAbs) and cytokine therapy. MAbs are sub-segmented into naked mAbs, conjugated mAbs and bispecific mAbs. Checkpoint inhibitors are sub-segmented into programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3).

By application, the market is segmented into cancer, autoimmune diseases and chronic inflammatory diseases.

By region, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segment will cover a detailed analysis of the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. Market data is provided for 2024 the base year, with forecasts for 2025 and a forecast value for 2030.

The report aims to:

• Analyze types of immunotherapies.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts through 2030.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the immunotherapy drug market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.